NGL Fine - Chem Share Price

Conference Call with NGL Fine - Chem Management and Analysts on Q4FY26 & Full Year Performance and Outlook. Listen to the full earnings transcript.

• Trendlyne
• 1 month ago

Pharmaceuticals company NGL Fine - Chem announced Q4FY26 & FY26 results Standalone Financial Highlights: Revenue from Operations: Q4FY26: Rs 14,474.55 lakh, compared to Rs 12,633.09 lakh in Q3FY26 (QoQ increase of 14.58%) and Rs 9,301.75 lakh in Q4FY25 (YoY increase of 55.61%). FY26: Rs 48,877.38 lakh, compared to Rs 35,929.35 lakh in FY25 (YoY increase of 36.04%). Total Income: Q4FY26: Rs 14,725.73 lakh, compared to Rs 13,101.94 lakh in Q3FY26 (QoQ increase of 12.39%) and Rs 9,222.73 lakh in Q4FY25 (YoY increase of 59.67%). FY26: Rs 50,362.62 lakh, compared to Rs 36,905.19 lakh in FY25 (YoY increase of 36.46%). Profit after tax: Q4FY26: Rs 1,135.42 lakh, compared to Rs 1,473.62 lakh in Q3FY26 (QoQ decrease of 22.95%) and Rs (52.06) lakh in Q4FY25. FY26: Rs 4,163.22 lakh, compared to Rs 1,813.20 lakh in FY25 (YoY increase of 129.61%). Consolidated Financial Highlights: Revenue from Operations: Q4FY26: Rs 14,923.28 lakh, compared to Rs 12,750.99 lakh in Q3FY26 (QoQ increase of 17.04%) and Rs 9,497.14 lakh in Q4FY25 (YoY increase of 57.13%). FY26: Rs 50,095.47 lakh, compared to Rs 36,825.67 lakh in FY25 (YoY increase of 36.03%). Total Income: Q4FY26: Rs 15,169.20 lakh, compared to Rs 13,212.14 lakh in Q3FY26 (QoQ increase of 14.81%) and Rs 9,400.58 lakh in Q4FY25 (YoY increase of 61.36%). FY26: Rs 51,568.29 lakh, compared to Rs 37,688.70 lakh in FY25 (YoY increase of 36.83%). Profit after tax: Q4FY26: Rs 1,348.56 lakh, compared to Rs 1,569.07 lakh in Q3FY26 (QoQ decrease of 14.05%) and Rs 54.36 lakh in Q4FY25. FY26: Rs 4,812.67 lakh, compared to Rs 2,112.43 lakh in FY25 (YoY increase of 127.83%). Business Highlights: Dividend: The Board recommended a final dividend of Rs 1.75 per fully paid-up equity share of Rs 5 each for FY26, subject to shareholder approval at the AGM. Board Appointments: Mr. Rajesh Lawande was re-appointed as a Whole-Time Director for five consecutive years effective June 1, 2026. Mrs. Sarala Menon was re-appointed as a Managing Director for five consecutive years effective December 14, 2026. Auditors: M/s. KD Practice Consulting Pvt. Ltd. was appointed as Internal Auditor for FY27. M/s. Sanghavi Randeria & Associates was appointed as Cost Auditor for FY27. AGM: The 45th Annual General Meeting is scheduled for Tuesday, August 25, 2026, via Video Conferencing or Other Audio Visual Means. Segment Reporting: The Group operates in only one reportable primary business segment, 'Pharmaceuticals'. Other Matters: The auditors noted that figures for the quarter ended March 31, 2026, are the balancing figures between the audited figures for the full financial year and the published year-to-date figures up to the third quarter. There are no qualifications in the audit report. Result PDF

• Trendlyne
• 1 month ago

Conference Call with NGL Fine - Chem Management and Analysts on Q4FY24 Performance and Outlook. Listen to the full earnings transcript.

• Trendlyne
• 2 years 1 month ago